Biotech Company Accelerates AI Detection Breakthrough Globally
Source: Streetwise Reports  (3/20/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors. More >

Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity
Source: Streetwise Reports  (3/20/26)
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts. More >

Life Sciences Firm Advances Massive US$2.4B Market Opportunity
Source: Streetwise Reports  (3/18/26)
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii. More >

An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum
Source: Stewart Thomson  (3/17/26)
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA). More >

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
Source: Andrew Fein  (3/16/26)
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market. More >

Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands
Source: Dr. Yi Chen  (3/13/26)
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note. More >

Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data
Source: Dr. Douglas Loe  (3/11/26)
Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy. More >

A New Infection Control Platform Launched
Source: John Newell  (3/11/26)
John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy. More >

Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"
Source: Dr. Douglas Loe  (3/9/26)
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts. More >

Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential
Source: Streetwise Reports  (3/9/26)
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%. More >

Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory
Source: Dr. Douglas Loe  (3/6/26)
Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow. More >

Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M
Source: Nicholas Cortellucci  (3/5/26)
Atrium Research initiated coverage on Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30. More >

Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing
Source: Streetwise Reports  (3/5/26)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) successfully secured financing transactions totaling CA$7.1 million, significantly bolstering the company's financial stability. Find out how one analyst rates the stock. More >

Biotech Expands Financing to CA$2M as AI-Driven Cancer Drug Programs Advance
Source: Streetwise Reports  (2/24/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) increased its previously announced financing to approximately US$2.0 million through a convertible debenture and private placement. The company stated the proceeds will support working capital needs and ongoing corporate and strategic initiatives. More >

New Data, Analyst Calls, and Pipeline Milestones Put Spotlight on Next Wave of Weight-Loss Drug Developers
Source: Streetwise Reports  (2/18/26)
Eli Lilly (LLY:NYSE), Amgen (AMGN:NASDAQ), and Structure Therapeutics (GPCR:NASDAQ) were cited in recent reports and corporate updates tied to the expanding GLP-1 and obesity treatment market. Analyst commentary, clinical developments, and pipeline milestones highlighted ongoing activity across the sector. More >

Biotech Company Advances Breakthrough Hyperinsulinism Treatment
Source: Streetwise Reports  (2/13/26)
Rezolute Inc. (RZLT:NASDAQ), a late-stage company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), reports its financial results and provides a business update for the three months ending December 31, 2025. Read why one analyst considers the stock a Buy. More >

Technically Oversold with Support, Solid Patents, & A Heavyweight Board: Is This Stock Set to Soar?
Source: Stewart Thomson  (2/10/26)
Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent. More >

CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Source: Streetwise Reports  (2/10/26)
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives. More >

Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies
Source: Streetwise Reports  (2/9/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates. More >

FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results
Source: Streetwise Reports  (2/6/26)
TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study. More >

Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
Source: Streetwise Reports  (2/2/26)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year. More >

Biopharma Reaches 50% Enrollment in New ALS Drug Program
Source: Jason Kolbert  (2/2/26)
MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm. More >

Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market
Source: Streetwise Reports  (1/30/26)
Biopharmaceutical firm MediciNova Inc. (MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year. More >

Clean Tech Developer Sees Massive Opportunity in PFAS Treatment
Source: Streetwise Reports  (1/29/26)
BioLargo Inc. (BLGO:OTCQX) announces that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed in New Jersey. Find out why the company sees massive upside for its products. More >

Environmental Firm Finds High-Value Position in PFAS Remediation Industry
Source: Streetwise Reports  (1/28/26)
BioLargo Inc. (BLGO:OTCQX) has announced the installation of its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system in New Jersey. Discover why the company anticipates significant potential for its products. More >